Covestor LTD Halozyme Therapeutics, Inc. Transaction History

Covestor LTD

$160 Million
Q3 2024

A detailed history of Covestor LTD transactions in Halozyme Therapeutics, Inc. stock. As of the latest transaction made, Covestor LTD holds 1,777 shares of HALO stock, worth $99,103. This represents 0.06% of its overall portfolio holdings.

Number of Shares

1,777

Previous 2,052 13.4%

Holding current value

$99,103

Previous $107,000 4.67%

% of portfolio

0.06%

Previous 0.07%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 01, 2024	SELL	$51.3 - $64.42 $14,107 - $17,715	-275 Reduced 13.4%	1,777 $102,000
Q2 2024 Aug 09, 2024	SELL	$37.81 - $52.4 $19,699 - $27,300	-521 Reduced 20.25%	2,052 $107,000
Q1 2024 May 10, 2024	BUY	$33.68 - $41.95 $49,711 - $61,918	1,476 Added 134.55%	2,573 $105,000
Q4 2023 Feb 09, 2024	BUY	$33.32 - $42.1 $16,060 - $20,292	482 Added 78.37%	1,097 $41,000
Q3 2023 Nov 13, 2023	SELL	$36.46 - $44.03 $11,193 - $13,517	-307 Reduced 33.3%	615 $24,000
Q2 2023 Aug 11, 2023	BUY	$30.28 - $38.74 $19,288 - $24,677	637 Added 223.51%	922 $33,000
Q1 2023 May 15, 2023	SELL	$32.86 - $55.7 $25,236 - $42,777	-768 Reduced 72.93%	285 $11,000
Q4 2022 Feb 13, 2023	SELL	$40.06 - $59.44 $28,642 - $42,499	-715 Reduced 40.44%	1,053 $59,000
Q3 2022 Nov 14, 2022	BUY	$38.53 - $51.78 $41,882 - $56,284	1,087 Added 159.62%	1,768 $70,000
Q2 2022 Aug 10, 2022	SELL	$37.35 - $48.3 $36,603 - $47,334	-980 Reduced 59.0%	681 $30,000
Q1 2022 May 13, 2022	SELL	$31.97 - $41.06 $37,277 - $47,875	-1,166 Reduced 41.25%	1,661 $66,000
Q4 2021 Feb 10, 2022	BUY	$31.82 - $40.75 $89,955 - $115,200	2,827 New	2,827 $114,000

Others Institutions Holding HALO

# of Institutions

539

Shares Held

126M

Call Options Held

294K

Put Options Held

180K

View Full List

About HALOZYME THERAPEUTICS, INC.

Ticker HALO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 139,288,992
Market Cap $7.77B
Description
Halozyme Therapeutics, Inc. operates as a biopharma technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company's products are based on the ENHANZE drug delivery technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable...

More about HALO

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Covestor LTD, based on Form 13F filings with the SEC.

News

Stay updated on Covestor LTD with notifications on news.

Account